Mirum Pharmaceuticals is a biotech headquartered in USA. Over the past three years, Mirum Pharmaceuticals has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 14 active clinical trials, primarily in Infectious.
Deals (12mo)
2
Active Trials
14
Top Modality
Small Molecules
Focus Area
Infectious
Licensing, acquisition, and partnership transactions involving Mirum Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| phase 3 hepatitis B/D drug | Bluejay Therapeutics | Small Molecules | Phase 3 | acquisition | Mar 2026 |
Therapeutic areas and modalities where Mirum Pharmaceuticals is most active based on deal history and clinical trial data.
Key indicators of Mirum Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Mirum Pharmaceuticals has 14 active clinical trials across 4 development phases.
4
Unknown
1
Phase 4
6
Phase 2
3
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Mirum Pharmaceuticals is a biotech company based in USA that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Mirum Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Mirum Pharmaceuticals include Infectious (4 deals and trials), Infectious Disease (2 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Mirum Pharmaceuticals has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Mirum Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Mirum Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
Industry-wide analysis of deal terms, trends, and market dynamics
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals